The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
Pazina, Tatiana, James, Ashley M., MacFarlane, Alexander W., Bezman, Natalie A., Henning, Karla A., Bee, Christine, Graziano, Robert F., Robbins, Michael D., Cohen, Adam D., Campbell, Kerry S.Мова:
english
Журнал:
OncoImmunology
DOI:
10.1080/2162402X.2017.1339853
Date:
June, 2017
Файл:
PDF, 3.40 MB
english, 2017